AI-Native Scoping Reviews & Evidence Mapping

LLM documentation is not simply “safe” or “unsafe”: this evidence map shows where hallucination risk becomes measurable, where it falls below human benchmarks, and which safeguards actually matter—RAG, verification loops, fine-tuning, and human review. Built from 46 references and 32 original studies, it turns scattered clinical AI documentation evidence into a practical safety map for deciding whether, where, and how LLMs should enter real clinical workflows.

ChatGPT vs Claude is not a contest with one winner: the evidence map shows that model performance flips by task, version, modality, and risk level across medicine, education, coding, safety, and research workflows. The full evidence map turns scattered benchmark studies into a practical guide for choosing the right model, identifying where human oversight is essential, and understanding where each system actually performs best.

LinkedIn and Twitter/X are not interchangeable platforms: this evidence map shows where LinkedIn better supports professional identity, recruitment, institutional signaling, and provider-targeted outreach, while Twitter/X more often drives rapid dissemination, public conversation, and broader engagement. The full read turns scattered studies across healthcare, academia, business, government, and computational research into a practical platform-by-platform guide for choosing the right channel, audience, and outcome.

Instagram is not simply harmful or helpful for mental health: the evidence shows a conditional ecosystem where comparison, nighttime use, Reels, body-image pressure, misinformation, and harassment coexist with peer support, psychoeducation, stigma reduction, and help-seeking. The full read maps where the strongest signals sit across depression, anxiety, sleep, self-harm, body image, digital detox, and platform safety — turning a noisy public debate into a clinically useful evidence map.

This paper shows that OMT is not confined to musculoskeletal symptom relief, but sits at the intersection of pain modulation, autonomic regulation, neonatal care, and selected inpatient applications, with its strongest recurrent signal in chronic low back pain. The full read is worth it because it separates where the evidence is genuinely convincing, where mechanistic findings deepen the clinical story, and where the field still rests on mixed or low-certainty data.

This paper shows that women usually live longer than men, but that extra survival often comes with more years lived with disability, multimorbidity, and reduced independence rather than more healthy years. The full paper is worth reading because it shows where the female advantage remains strong, where it weakens, and which conditions and life circumstances most clearly explain the difference.

YouTube is not simply good or bad for mental health: it is a powerful bidirectional ecosystem where psychoeducation, peer support, and low-threshold interventions coexist with misinformation, stigma, harmful comments, self-diagnosis, sleep disruption, and distress-amplifying use. The full evidence map helps clinicians, researchers, and platform designers see which YouTube exposures are beneficial, which are risky, and where the strongest signals emerge across 249 original studies.

Hyaluronic acid fillers are more than simple volumizers: their real clinical value depends on product rheology, anatomical placement, imaging guidance, and rapid complication rescue. The full evidence map helps separate durable aesthetic and reconstructive benefits from the safety boundaries that matter most in practice, including vascular occlusion, delayed inflammation, migration, hyaluronidase response, and rare ocular or neurologic events.

Cannabis legalization is not a single public-health story: the strongest signal emerges after commercialization, where higher use, ED visits, hyperemesis, pediatric exposures, psychosis-related harms, and vulnerable-population risks become more visible. The full SAIMSARA evidence map is worth reading because it separates legalization, retail expansion, potency, packaging, taxation, risk perception, and clinical-risk groups across 175 references and 533 original studies.

This review maps 995 original studies and 26.6 million participants comparing apixaban and rivaroxaban across AF, VTE, CKD, cirrhosis, cancer, elderly, and other high-risk populations. It delivers a clear human- and machine-ready signal: apixaban shows a more favorable bleeding profile, while rivaroxaban remains relevant in selected adherence, cost, VTE, and orthopedic contexts.

Therapeutic drug monitoring of antibiotics turns dosing from guesswork into measurable precision, especially in critically ill, pediatric, burn, ECMO, renal-replacement, and other high-risk patients where standard regimens often miss PK/PD targets. This SAIMSARA evidence map is worth reading because it separates practical dosing signals from implementation noise, mapping β-lactams, vancomycin, aminoglycosides, toxicity thresholds, assay reliability, digital dosing tools, and stewardship workflows across 394 original studies.